Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone for Neovascular AMD

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2008 by Shahid Beheshti Medical University.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Shahid Beheshti Medical University
ClinicalTrials.gov Identifier:
NCT00370370
First received: August 30, 2006
Last updated: June 25, 2008
Last verified: June 2008
  Purpose

To compare the efficacy and safety results of intravitreal bevacizumab alone with bevacizumab + triamcinolone acetonide in neovascular AMD.


Condition Intervention Phase
Neovascular Age-Related Macular Degeneration
Drug: bevacizumab
Drug: bevacizumab + triamcinolone acetonide
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Shahid Beheshti Medical University:

Primary Outcome Measures:
  • visual acuity

Secondary Outcome Measures:
  • central macular thickness
  • leakage in fluorescein angiography
  • intraocular pressure
  • anterior chamber reaction

Study Start Date: November 2005
Arms Assigned Interventions
Active Comparator: 1
Injection of intravitreal bevacizumab
Drug: bevacizumab
Injection of intravitreal bevacizumab
Active Comparator: 2
Injection of bevacizumab + triamcinolone acetonide
Drug: bevacizumab + triamcinolone acetonide
Injection of bevacizumab + triamcinolone acetonide

  Eligibility

Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Cases of active neovascular AMD with visual acuity of 20/400- 20/40

Exclusion Criteria:

  • History of glaucoma or ocular hypertension
  • Disciform scar
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00370370

Locations
Iran, Islamic Republic of
Hamid Ahmadieh, MD
Tehran, Iran, Islamic Republic of, 16666
Sponsors and Collaborators
Shahid Beheshti Medical University
Investigators
Principal Investigator: Hamid Ahmadieh, MD Ophthalmic Research Center of Shaheed Beheshti Medical University
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00370370     History of Changes
Other Study ID Numbers: 8533
Study First Received: August 30, 2006
Last Updated: June 25, 2008
Health Authority: Iran: Ethics Committee

Keywords provided by Shahid Beheshti Medical University:
Bevacizumab,
Triamcinolone
Age-related macular degeneration
Choroidal neovascular membrane

Additional relevant MeSH terms:
Macular Degeneration
Wet Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Triamcinolone hexacetonide
Triamcinolone
Triamcinolone Acetonide
Triamcinolone diacetate
Bevacizumab
Anti-Inflammatory Agents
Therapeutic Uses
Pharmacologic Actions
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Immunosuppressive Agents
Immunologic Factors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents

ClinicalTrials.gov processed this record on April 14, 2014